These are the two largest overlapping clusters on this site — 38 articles tagged reishi, 30 tagged chaga — and they've never been put head to head. There's a reason the comparison is awkward. One of them has a Cochrane review, a 132-patient randomised trial and a dose range. The other has no randomised human trial of any kind. Reviewing them as equals would misrepresent both.
Reishi has the evidence: Tang 2005 randomised 132 patients with neurasthenia to 5.4 g/day of a polysaccharide extract or placebo for eight weeks, cutting the sense of fatigue 28.3% against 20.1% (51.6% rated more than minimally improved versus 24.6%, p = 0.002). A Cochrane review of five trials found no effect on HbA1c, cholesterol or BMI, so the picture is honest rather than glowing. Chaga has no randomised human trial and no established dose — and three published cases of oxalate nephropathy, one ending in dialysis-dependent end-stage renal disease.
We sell both, and chaga is the better seller of the two. That makes this the kind of comparison worth writing carefully.
What Human Evidence Does Reishi Actually Have?
Two useful datasets pointing in different directions. Tang's 2005 trial in Journal of Medicinal Food randomised 132 patients with neurasthenia to Ganopoly — a Ganoderma lucidum polysaccharide extract — at 1,800 mg three times daily, or placebo, for eight weeks. Among 123 assessable patients, the sense of fatigue fell 28.3% from baseline against 20.1% on placebo, and clinical global impression severity fell 15.5% against 4.9%.
The cleanest number in the paper is the responder rate: 51.6% of the reishi group (32 of 62) were rated more than minimally improved, against 24.6% (15 of 61) on placebo (p = 0.002).
Then the counterweight. Klupp's 2015 Cochrane review pooled five trials and 398 participants and found G. lucidum at 1.4 to 3 g/day over 12 to 16 weeks produced no statistically or clinically significant reduction in HbA1c (WMD −0.10%, 95% CI −1.05 to 0.85), total cholesterol, LDL or BMI. Risk of bias was low in one study and unclear in the other four.
So reishi's honest position is: something real on subjective fatigue and well-being, nothing on the metabolic markers people also buy it for.
What Human Evidence Does Chaga Have?
None of the same kind. There's no published randomised controlled trial of chaga in humans, and consequently no established dose. What exists is in vitro work, animal models and a small number of case reports.
Is that a reason to dismiss it? Not quite. The mechanistic literature on Inonotus obliquus is genuinely substantial, and absence of trials reflects who funds research rather than a failed experiment. But "we haven't tested this in people" and "this works" are different sentences, and chaga marketing routinely uses the second while resting on the first.
Why Does Chaga Outsell the Better-Evidenced Mushroom?
Largely on an antioxidant claim built from ORAC values — oxygen radical absorbance capacity, a test-tube measure of how a substance behaves toward free radicals in a cuvette. The USDA removed its ORAC database in 2012 on the grounds that the values had no demonstrated relevance to human biology.
Chaga scores spectacularly on a metric its own publisher withdrew. That's an uncomfortable foundation for a category-leading product, and our chaga antioxidant article takes the mechanism seriously without pretending the ORAC number means what the packaging implies.
The Safety Profiles Are Not Symmetric Either
This is where the comparison stops being about efficacy. Reishi's adverse effects are reaction-type: mild GI upset, dry mouth, occasional dizziness, with an antiplatelet caution that matters if you take anticoagulants. Stop taking it and the risk stops.
Chaga's principal hazard works differently. It's a cumulative oxalate load with a renal endpoint, and there are three published cases:
- Kikuchi 2014 — a 72-year-old woman took chaga powder at 4 to 5 teaspoons a day for six months after liver cancer surgery. Renal function declined, haemodialysis was started, and biopsy showed diffuse tubular atrophy with oxalate crystals in the tubules.
- Lee 2020 — a 49-year-old man reached end-stage renal disease after years of chaga powder for atopic dermatitis. The remaining powder was measured at 14.2 g oxalate per 100 g.
- Kwon 2022 — a 69-year-old man took 10 to 15 g of chaga powder daily with 500 mg of vitamin C for three months, and developed acute kidney injury presenting as nephrotic syndrome.
Notice what the third case implies. Ascorbate is metabolised to oxalate, so pairing chaga with a vitamin C supplement is the worst version of the stack — and it's exactly the combination a health-conscious buyer would assemble without thinking. Our chaga safety article covers all three cases in depth, and the chaga timing guide explains why co-ingestion, not clock time, is what matters for this species.
Side by Side
| Reishi | Chaga | |
|---|---|---|
| Randomised human trials | Yes — five in one Cochrane review, plus Tang 2005 | None published |
| Established dose | 1.4–5.4 g/day across trials | None |
| Best-supported use | Fatigue and subjective well-being | No human-tested use |
| Where it failed | HbA1c, cholesterol, LDL, BMI — all null | Never tested, so nothing to fail |
| Risk type | Reaction-type, reversible; antiplatelet caution | Cumulative oxalate load, renal endpoint |
| Documented serious harm | None published | Three nephropathy cases, one ESRD |
| Signature compounds | Triterpenes and beta-glucans | Betulin, betulinic acid, melanin complex |
Do They Even Do the Same Thing?
Not really, which is part of why the head-to-head is rarely written. Reishi is sold for calm, sleep and stress resilience, and its one solid trial measured fatigue and well-being. Chaga is sold for immune and antioxidant support, and has been tested for neither in humans.
Their chemistry differs too. Reishi's triterpenes need alcohol to extract properly, which is the real argument for dual extraction, covered in our triterpenes article. Chaga's betulin fraction is poorly water-soluble regardless of how long you simmer it, which is why format choice matters differently for each — see our chaga format guide.
Which One Should You Buy?
- If you want the mushroom with human evidence behind it, buy reishi. It's the only one of the two with a trial, a dose and a measured effect.
- If your goal is fatigue, sleep or stress, that's reishi too — those are the endpoints Tang measured. Our reishi dosage guide has the numbers.
- If you like chaga as a drink, drink it as a decoction rather than swallowing powder. Chunks leave much of the oxalate in the spent material; swallowed powder delivers all of it.
- Never pair chaga with a vitamin C supplement, and don't take it daily at gram scale for months on end.
- Don't take chaga at all if you have kidney disease or a history of kidney stones. This is the one clear contraindication in the comparison.
Frequently Asked Questions
Is reishi or chaga better for immunity?
Neither has a human immune trial with a clinical endpoint. Reishi has an uncontrolled before-and-after in advanced cancer patients; chaga has no human trial at all. If immunity is the goal, Trametes and shiitake have far better data, as our immunity ranking sets out.
Can you take reishi and chaga together?
No interaction between them is documented. The relevant caution is that stacking makes attribution impossible, and chaga's oxalate load doesn't get smaller because something else is in the cup. Start with one.
Which has more side effects?
Reishi has more frequent mild ones; chaga has the more serious documented harm. Three published cases of chaga-associated oxalate nephropathy exist, one progressing to end-stage renal disease. No comparable case has been published for reishi.
Is chaga worth taking if there are no trials?
That's a judgement call, not a factual question. What's factual is that no randomised human trial exists, no dose has been established, and the known risk accumulates with total exposure. Occasional use as a drink sits differently from daily gram-scale powder for months.
How long does reishi take to work?
Tang's trial measured at eight weeks, and the Cochrane trials ran 12 to 16. Eight weeks is a reasonable floor for a self-test; anything shorter is unlikely to show you what the trials showed.
Shop Reishi and Chaga
Reishi capsules (120 caps €39, 2 × 120 €70) and dried reishi (100 g €49, 1 kg €349) cover the species with the trial record. Chaga chunks (100 g €25, 300 g €39, 1 kg €59) are both the cheapest chaga format and the lower-oxalate one, since much of it stays in the spent material — we'd steer you here over chaga capsules (120 caps €39) for that reason. Free shipping on orders over €50.
Related Articles
- Reishi Dosage Guide
- Chaga Dosage Guide
- Chaga Side Effects and Interactions
- Reishi Side Effects and Interactions
- Chaga: Powder vs Chunks vs Extract
- Reishi: Powder vs Capsules vs Tincture
- Best Mushrooms for Immunity
Sources
- Tang W, Gao Y, Chen G, et al. A randomized, double-blind and placebo-controlled study of a Ganoderma lucidum polysaccharide extract in neurasthenia. J Med Food. 2005;8(1):53-58. PubMed 15857210
- Klupp NL, Chang D, Hawke F, et al. Ganoderma lucidum mushroom for the treatment of cardiovascular risk factors. Cochrane Database Syst Rev. 2015;(2):CD007259. PubMed 25686270
- Kikuchi Y, Seta K, Ogawa Y, et al. Chaga mushroom-induced oxalate nephropathy. Clin Nephrol. 2014;81(6):440-444. PubMed 23149251
- Lee S, Lee HY, Park Y, et al. Development of end stage renal disease after long-term ingestion of chaga mushroom: case report and review of literature. J Korean Med Sci. 2020;35(19):e122. PubMed 32419395
- Kwon O, Kim Y, Paek JH, et al. Chaga mushroom-induced oxalate nephropathy that clinically manifested as nephrotic syndrome: a case report. Medicine (Baltimore). 2022;101(10):e28997. PubMed 35451393
- Gao Y, Zhou S, Jiang W, Huang M, Dai X. Effects of ganopoly (a Ganoderma lucidum polysaccharide extract) on the immune functions in advanced-stage cancer patients. Immunol Invest. 2003;32(3):201-215. PubMed 12916709